Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : BX-001N
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : (BX-001N) is currently being evaluated in Phase II clinical studies for the treatment of Reperfusion Injury.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
September 10, 2025
Lead Product(s) : BX-001N
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : BX-001N
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Evaluate the Safety and Pharmacokinetics of BX-001N in Healthy Participants
Details : BX-001N is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Reperfusion Injury.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
October 24, 2023
Lead Product(s) : BX-001N
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable